Pathstone Holdings LLC Increases Stock Position in Repligen Co. (NASDAQ:RGEN)

Pathstone Holdings LLC increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 32.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,284 shares of the biotechnology company’s stock after buying an additional 5,459 shares during the period. Pathstone Holdings LLC’s holdings in Repligen were worth $3,316,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Swedbank AB purchased a new stake in shares of Repligen during the first quarter worth about $5,518,000. First Turn Management LLC purchased a new stake in Repligen during the 3rd quarter worth approximately $13,202,000. Banque Pictet & Cie SA raised its position in shares of Repligen by 74.6% in the 2nd quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock valued at $4,351,000 after purchasing an additional 14,746 shares in the last quarter. Geneva Capital Management LLC boosted its stake in shares of Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after buying an additional 10,908 shares during the last quarter. Finally, Diversified Trust Co grew its position in shares of Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after buying an additional 106 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on RGEN. Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company started coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $142.58 on Monday. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The firm has a market capitalization of $7.99 billion, a PE ratio of -385.34, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 5.56. The business’s fifty day moving average price is $140.26 and its two-hundred day moving average price is $143.27.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same period last year, the firm posted $0.23 EPS. Repligen’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, research analysts expect that Repligen Co. will post 1.52 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.